The ELCC 2022 virtual programme is now available!
- Update your knowledge in prevention, screening and early detection of thoracic malignancies
- Review the current state-of-the-art in perioperative management of localised lung cancer and in systemic therapy of advanced tumours
- Learn how to best sequence or combine therapies in advanced non-small cell lung cancer
- Review the current and emerging contribution of precision medicine, big data and artificial intelligence, biomarkers and liquid biopsies in the optimal management of patients with thoracic malignancies
ESMO-MORA: The ELCC 2022 Congress programme has been accredited with 21 Cat. 1 ESMO MORA points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.
The Congress webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted. ESMO Members who do not register for the Congress will have access to the resources 2 months after the end of the congress.